Physician profile
Eric Bracken
NPI 1336553353
$1,031.43
in general payments reported to CMS, 2019-2025
14 companies · $69.56 in 2025
The $69.56 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $551 · 2020: $124 · 2021: $178 · 2023: $39.13 · 2024: $69.33 · 2025: $69.56.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $178.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $178.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $257.13 | 2019-2025 | Briviact |
| Biogen, INC. | $183.85 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $128.88 | 2020-2021 | |
| Amgen INC. | $120.80 | 2019 | |
| Portola Pharmaceuticals, LLC | $110.11 | 2019 | |
| Janssen Pharmaceuticals, INC | $60.98 | 2021-2023 | Xarelto |
| Novartis Pharmaceuticals Corporation | $35.98 | 2019 | |
| Pfizer INC. | $30.47 | 2020-2021 | |
| Medtronic, INC. | $27.90 | 2025 | Linq II |
| Merck Sharp & Dohme LLC | $22.06 | 2023 | Recarbrio, Zerbaxa, Dificid |
| Eisai INC. | $15.12 | 2019 | |
| Allergan, INC. | $14.17 | 2020 | |
| Neuropace, INC. | $11.99 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $11.99 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Bracken listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.